Actively Recruiting
Zynrelef vs Exparel: The Battle of Postoperative Pain Control After Robotic Sleeve Gastrectomy
Led by Texas Tech University Health Sciences Center · Updated on 2025-03-21
130
Participants Needed
1
Research Sites
56 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the use of an injectable combination of bupivacaine and meloxicam (Zynrelef) vs injectable liposomal bupivacaine (Exparel), two extended local anesthesia strategies currently approved by FDA and on the market for post-surgical pain control. The investigators plan on randomizing study participants to either Exparel or Zynrelef at the closure site of robotic sleeve gastrectomy and assessing their pain control postoperatively both in the hospital and at home. The investigators will measure the outcome of two drugs, Zynrelief, and Exparel on postoperative pain score -using the NRS pin score up to 72 hours after surgery. The total opioid use will be recorded in forms that will be used to measure pain score and total opioid use and will be collected to the Excel sheet. The cost of the drug will be calculated for internal use for Hospital purpose only.
CONDITIONS
Official Title
Zynrelef vs Exparel: The Battle of Postoperative Pain Control After Robotic Sleeve Gastrectomy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 65 years old
- Scheduled or planned to have robotic sleeve gastrectomy by Dr. Goyal
- Able to provide written informed consent
- Able to follow study visit schedule and complete all assessments
You will not qualify if you...
- Positive urine drug screen before surgery
- History of substance abuse in the past year by self-report
- Daily narcotic use at the time of surgery by self-report
- Unable to understand informed consent or read English/Spanish
- Pregnant or lactating patients
- Prisoners
- Patients with kidney or liver failure
- Use of bupivacaine within 96 hours before surgery
- Intolerance or contraindication to opiates, nonsteroidal anti-inflammatory drugs, acetaminophen, Zynrelef, or Exparel
- History of asthma, urticaria, or allergic reactions to aspirin or NSAIDs, including severe anaphylaxis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Texas Tech University Health Sciences Center
Lubbock, Texas, United States, 79430
Actively Recruiting
Research Team
T
Tommy Wright, DO
CONTACT
V
Vinay Goyal, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here